Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more
Autolus Therapeutics plc (6A3A) - Total Liabilities
Latest total liabilities as of September 2025: €396.50 Million EUR
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has total liabilities worth €396.50 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Autolus Therapeutics plc - Total Liabilities Trend (2017–2024)
This chart illustrates how Autolus Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Autolus Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Autolus Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MAKUS Inc
KQ:093520
|
Korea | ₩138.88 Billion |
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
USA | $25.38 Million |
|
Vuzix Corp.
LSE:0LRL
|
UK | $4.59 Million |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
Taiwan | NT$3.07 Billion |
|
Gamania Digital Entertainment Co Ltd
TWO:6180
|
Taiwan | NT$3.32 Billion |
|
Melar Acquisition Corp. I Class A Ordinary Shares
NASDAQ:MACI
|
USA | $10.89 Million |
|
Ege Gubre Sanayi AS
IS:EGGUB
|
Turkey | TL1.79 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Autolus Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Autolus Therapeutics plc (2017–2024)
The table below shows the annual total liabilities of Autolus Therapeutics plc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €355.40 Million | +34.67% |
| 2023-12-31 | €263.91 Million | +37.74% |
| 2022-12-31 | €191.60 Million | +107.72% |
| 2021-12-31 | €92.24 Million | +9.54% |
| 2020-12-31 | €84.20 Million | +72.93% |
| 2019-12-31 | €48.69 Million | +174.49% |
| 2018-12-31 | €17.74 Million | +192.69% |
| 2017-12-31 | €6.06 Million | -- |